{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:51:43Z","timestamp":1787752303117,"version":"build-2784847793"},"reference-count":291,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.dld.2021.06.021","type":"journal-article","created":{"date-parts":[[2021,7,25]],"date-time":"2021-07-25T23:28:44Z","timestamp":1627255724000},"page":"1089-1104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF)"],"prefix":"10.1016","volume":"53","author":[{"given":"Raffaele","family":"Bruno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero","family":"Camm\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Caraceni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazio","family":"Grattagliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"La Mura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliviero","family":"Riggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Schepis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Senzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3486-7097","authenticated-orcid":false,"given":"Roberto","family":"de Franchis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2021.06.021_bib0001","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0002","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2010.05.004","article-title":"EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis","volume":"53","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0003","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/intqhc\/mzi108","article-title":"Adaptation of clinical guidelines: literature review and proposition for a framework and procedure","volume":"18","author":"Fervers","year":"2006","journal-title":"Int J Qual Health Care"},{"key":"10.1016\/j.dld.2021.06.021_bib0004","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/bmjqs.2010.043257","article-title":"Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation","volume":"20","author":"Fervers","year":"2011","journal-title":"BMJ Qual Saf"},{"key":"10.1016\/j.dld.2021.06.021_bib0005","doi-asserted-by":"crossref","first-page":"E78","DOI":"10.1503\/cmaj.081232","article-title":"Adapting clinical practice guidelines to local context and assessing barriers to their use","volume":"182","author":"Harrison","year":"2010","journal-title":"CMAJ"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2021.06.021_bib0006","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1002\/hep.20993","article-title":"The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule","volume":"43","author":"Iwakiri","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0007","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.path.2013.03.006","article-title":"Cirrhosis regression and subclassification","volume":"6","author":"Bedossa","year":"2013","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.dld.2021.06.021_bib0008","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hep.28264","article-title":"Development of hyperdynamic circulation and response to \u03b2-blockers in compensated cirrhosis with portal hypertension","volume":"63","author":"Villanueva","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0009","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D'Amico","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0010","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0168-8278(02)00420-8","article-title":"Incidence and natural history of small esophageal varices in cirrhotic patients","volume":"38","author":"Merli","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0011","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/apt.12721","article-title":"Competing risks and prognostic stages in cirrhosis: a 25-year inception cohort study of 494 patients","volume":"39","author":"D'Amico","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.06.021_bib0012","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1572-0241.2000.01775.x","article-title":"Natural history of cirrhotic patients with small esophageal varices: a prospective study","volume":"95","author":"Zoli","year":"2000","journal-title":"Am J Gastro"},{"key":"10.1016\/j.dld.2021.06.021_bib0013","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/S0168-8278(00)80320-7","article-title":"Updating consensus in portal hypertension: report of the Baveno III consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension","volume":"33","author":"De Franchis","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0014","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.gastro.2013.10.018","article-title":"A MELD-based model to determine risk of mortality among patients with acute variceal bleeding","volume":"146","author":"Reverter","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0015","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1053\/jhep.2003.50385","article-title":"Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators","volume":"38","author":"D'Amico","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0016","first-page":"63","article-title":"Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis","volume":"25","author":"Bernard","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0017","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1055\/s-2007-1007133","article-title":"Pharmacological treatment of portal hypertension: an evidence-based approach","volume":"19","author":"D'Amico","year":"1999","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.dld.2021.06.021_bib0018","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1111\/j.1478-3231.2012.02830.x","article-title":"Prognostic indicators of survival in patients with compensated and decompensated cirrhosis","volume":"32","author":"Zipprich","year":"2012","journal-title":"Liv Int"},{"key":"10.1016\/j.dld.2021.06.021_bib0019","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jhep.2015.07.004","article-title":"Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilatation to systemic inflammation hypothesis","volume":"63","author":"Bernardi","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0020","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1053\/j.gastro.2007.06.020","article-title":"Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data","volume":"133","author":"Salerno","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0021","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/j.gastro.2016.09.016","article-title":"Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites","volume":"152","author":"Bureau","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0022","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/hep.23500","article-title":"Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study","volume":"51","author":"Jepsen","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0023","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jhep.2013.03.039","article-title":"Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites","volume":"59","author":"Piano","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0024","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/gutjnl-2011-301255","article-title":"Acute kidney injury in decompensated cirrhosis","volume":"62","author":"Tsien","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.06.021_bib0025","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jhep.2011.10.016","article-title":"Renal Failure and cirrhosis: a systematic review of mortality and prognosis","volume":"56","author":"Fede","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0026","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1053\/jhep.2002.30082","article-title":"Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis","volume":"35","author":"Fernandez","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0027","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/ajg.2017.253","article-title":"Predictors of early readmission in patients with cirrhosis after the resolution of bacterial infections","volume":"112","author":"Piano","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.06.021_bib0028","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1053\/j.gastro.2010.06.019","article-title":"Infections in patients with cirrhosis increases mortality four-fold and should be used in determining prognosis","volume":"139","author":"Arvaniti","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0029","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cgh.2007.02.039","article-title":"Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis","volume":"5","author":"Ioannou","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0030","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/hep.27443","article-title":"Prognosis of untreated hepatocellular carcinoma","volume":"61","author":"Giannini","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0031","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1053\/j.gastro.2013.02.042","article-title":"Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis","volume":"144","author":"Moreau","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0032","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jhep.2017.07.008","article-title":"Incidence, predictors and outcome of acute-on-chronic liver failure in outpatients with cirrhosis","volume":"67","author":"Piano","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0033","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","article-title":"Clinical states of cirrhosis and competing risks","volume":"68","author":"D'Amico","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0034","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1053\/j.gastro.2012.02.017","article-title":"Noninvasive methods to assess liver disease in patients with hepatitis B or C","volume":"142","author":"Castera","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0035","series-title":"Proceedings of the Fifth Baveno International Consensus Workshop. de Franchis R","first-page":"18","article-title":"Elastography in the non-invasive evaluation of the extent of fibrosis and in the diagnosis of portal hypertension","author":"Castera","year":"2011"},{"key":"10.1016\/j.dld.2021.06.021_bib0036","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.cgh.2018.12.038","article-title":"Patients with Signs of Advanced Liver Disease and Clinically Significant Portal Hypertension Do Not Necessarily Have Cirrhosis","volume":"17","author":"Rodrigues","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0037","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Faculty. Expanding consensus in portal hypertension. Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0038","doi-asserted-by":"crossref","first-page":"e95776","DOI":"10.1371\/journal.pone.0095776","article-title":"Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease","volume":"9","author":"Pang","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.dld.2021.06.021_bib0039","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1053\/j.gastro.2008.01.034","article-title":"Performance of transient elastography for the staging of liver fibrosis: a meta-analysis","volume":"134","author":"Friedrich-Rust","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0040","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMoa044456","article-title":"Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis","volume":"353","author":"Groszmann","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.06.021_bib0041","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis","volume":"133","author":"Ripoll","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0042","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jhep.2010.06.004","article-title":"Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension","volume":"53","author":"de Franchis","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0043","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/hep.21907","article-title":"Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis","volume":"46","author":"Garcia-Tsao","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0044","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/liv.13318","article-title":"Liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding","volume":"37","author":"Marot","year":"2017","journal-title":"Liver International"},{"key":"10.1016\/j.dld.2021.06.021_bib0045","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jhep.2018.05.019","article-title":"Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis","volume":"69","author":"Petta","year":"2018","journal-title":"J Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0046","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jhep.2018.06.013","article-title":"Ruling out esophageal varices in NAFLD cirrhosis: can we do without endoscopy?","volume":"69","author":"de Franchis","year":"2018","journal-title":"J Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0047","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41395-018-0265-7","article-title":"Non-Invasive Prediction of High-Risk Varices in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis","volume":"114","author":"Moctezuma-Velazquez","year":"2019","journal-title":"Am J. Gastroenterol"},{"key":"10.1016\/j.dld.2021.06.021_bib0048","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/hep.1840050313","article-title":"Portal pressure, presence of gastroesophageal varices and variceal bleeding","volume":"5","author":"Garcia-Tsao","year":"1985","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0049","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0016-5085(98)70436-6","article-title":"Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings","volume":"114","author":"Casado","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0050","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1053\/j.gastro.2017.01.011","article-title":"Timing Affects Measurement of Portal Pressure Gradient After Placement of Transjugular Intrahepatic Portosystemic Shunts in Patients With Portal Hypertension","volume":"152","author":"Silva-Junior","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0051","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/qjmed\/91.1.19","article-title":"Haemodynamic parameters predicting variceal haemorrhage and survival in alcoholic cirrhosis","volume":"91","author":"Stanley","year":"1998","journal-title":"QJM"},{"key":"10.1016\/j.dld.2021.06.021_bib0052","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1053\/jhep.2000.19322","article-title":"The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis","volume":"32","author":"Merkel","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0053","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00535-010-0360-z","article-title":"Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension","volume":"46","author":"Berzigotti","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.dld.2021.06.021_bib0054","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2017.12.027","article-title":"Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis","volume":"68","author":"Turco","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0055","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0016-5085(99)70455-5","article-title":"Prognostic value of early measurements of portal pressure in acute variceal bleeding","volume":"117","author":"Moitinho","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0056","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/hep.20386","article-title":"Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding","volume":"40","author":"Monescillo","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0057","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jhep.2007.10.008","article-title":"Spanish Cooperative Group for Portal Hypertension and Variceal Bleeding. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy","volume":"48","author":"Abraldes","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0058","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1572-0241.2006.00453.x","article-title":"Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis","volume":"101","author":"Turnes","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.06.021_bib0059","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/ajg.2011.456","article-title":"Development of ascites in compensated cirrhosis with severe portal hypertension treated with \u03b2-blockers","volume":"107","author":"Hern\u00e1ndez-Gea","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.06.021_bib0060","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/hep.1840360612","article-title":"Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis","volume":"36","author":"Ba\u00f1ares","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0061","doi-asserted-by":"crossref","first-page":"702","DOI":"10.5009\/gnl16478","article-title":"Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: an Open Randomized Controlled Pilot Study","volume":"11","author":"Lim","year":"2017","journal-title":"Gut Liver"},{"key":"10.1016\/j.dld.2021.06.021_bib0062","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.gastro.2012.10.001","article-title":"Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis","volume":"144","author":"Berzigotti","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0063","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1053\/j.gastro.2018.01.028","article-title":"Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis","volume":"154","author":"Sim\u00f3n-Talero","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0064","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1056\/NEJMoa0910102","article-title":"Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Cooperative Study Group. Early use of TIPS in patients with cirrhosis and variceal bleeding","volume":"362","author":"Garc\u00eda-Pag\u00e1n","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.06.021_bib0065","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/hep.30314","article-title":"Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension","volume":"69","author":"Abraldes","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0066","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0067","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"\u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2021.06.021_bib0068","article-title":"Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults","volume":"8","author":"Gluud","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.dld.2021.06.021_bib0069","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.28992","article-title":"Effects of an intensive lifestyle intervention Program on portal hypertension in patients with Cirrhosis and obesity: the sportdiet study","volume":"65","author":"Berzigotti","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0070","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL Clinical Practice Guidelines: management of alcohol-related liver disease","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0071","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","article-title":"Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: a Systematic Review and Meta-analysis","volume":"15","author":"Kim","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0072","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0073","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jhep.2016.11.011","article-title":"Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease","volume":"66","author":"Lackner","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0074","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/hep.23500","article-title":"Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study","volume":"51","author":"Jepsen","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0075","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/0002-9343(68)90111-3","article-title":"Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease","volume":"44","author":"Powell","year":"1968","journal-title":"Am J Med"},{"key":"10.1016\/j.dld.2021.06.021_bib0076","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/gast.1996.v111.pm8780575","article-title":"Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study","volume":"111","author":"Vorobioff","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0077","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jhep.2016.01.034","article-title":"Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population","volume":"64","author":"Bruno","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0078","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/j.gastro.2016.03.036","article-title":"Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension","volume":"151","author":"Di Marco","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0079","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/j.gastro.2017.07.016","article-title":"Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis","volume":"153","author":"Lens","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0080","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0081","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0082","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","article-title":"Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients","volume":"71","author":"Cabibbo","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0083","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jhep.2018.03.009","article-title":"Newly diafnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study","volume":"69","author":"Romano","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0084","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0085","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2021.06.021_bib0086","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jhep.2015.06.006","article-title":"The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: a 12-year prospective cohort study","volume":"63","author":"Lampertico","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0087","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/apt.14848","article-title":"Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B","volume":"48","author":"Loglio","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.06.021_bib0088","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/hep.29320","article-title":"The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B","volume":"66","author":"Papatheodoridis","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0089","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0090","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jhep.2018.01.031","article-title":"Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population","volume":"68","author":"Papatheodoridis","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0091","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis","volume":"56","author":"D'Ambrosio","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0092","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jhep.2009.05.031","article-title":"Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension","volume":"51","author":"Manolakopoulos","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0093","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.cgh.2015.04.013","article-title":"Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy","volume":"13","author":"Lens","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0094","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jhep.2016.10.017","article-title":"Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication","volume":"66","author":"van der Meer","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0095","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3851\/IMP1807","article-title":"The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon\/ribavirin therapy","volume":"16","author":"D'Ambrosio","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.dld.2021.06.021_bib0096","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1053\/j.gastro.2004.05.004","article-title":"Gruppo Triveneto per l'Ipertensione Portale. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis","volume":"127","author":"Merkel","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0097","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12072-012-9353-8","article-title":"Early primary prophylaxis with beta-blockers does not prevent the growth of small esophageal varices in cirrhosis: a randomized controlled trial","volume":"7","author":"Sarin","year":"2013","journal-title":"Hepatol Int"},{"key":"10.1016\/j.dld.2021.06.021_bib0098","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/gutjnl-2016-311735","article-title":"Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial","volume":"66","author":"Bhardwaj","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.06.021_bib0099","first-page":"244A","article-title":"Hepatic venous pressure gradient (HVPG) predicts clinical disease progression in patients with compensated cirrhosis due to NASH","volume":"66","author":"Bosch","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0100","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/S0168-8278(17)30455-5","article-title":"Preventing decompensation of cirrhosis with clinically significant portal hypertension and without high-risk varices: a new indication for non-selective beta-blockers (NSBB)","volume":"66","author":"Villanueva","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.dld.2021.06.021_bib0101","doi-asserted-by":"crossref","first-page":"399","DOI":"10.7326\/0003-4819-149-6-200809160-00006","article-title":"Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C","volume":"149","author":"Mallet","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dld.2021.06.021_bib0102","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0103","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","article-title":"Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis","volume":"150","author":"Mohanty","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0104","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.06.021_bib0105","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.23340","article-title":"Efficacy and safety of peginterferon alfa 2a(40 KD) plus ribavirin in hepatitis c patients with advanced fibrosis and cirrhosis","volume":"51","author":"Bruno","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0106","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"Van der Meer","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2021.06.021_bib0107","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJM198810133191505","article-title":"North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study","volume":"319","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.06.021_bib0108","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1155\/2011\/346705","article-title":"Endoscopic band ligation versus pharmacological therapy for variceal bleeding in cirrhosis: a meta-analysis","volume":"25","author":"Li","year":"2011","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.dld.2021.06.021_bib0109","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/hep.23045","article-title":"Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed","volume":"50","author":"Tripathi","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0110","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2013.11.019","article-title":"Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial","volume":"60","author":"Shah","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0111","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1572-0241.2005.40468.x","article-title":"Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding","volume":"100","author":"Sarin","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.06.021_bib0112","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.gastro.2009.03.048","article-title":"Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding","volume":"137","author":"Villanueva","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0113","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/gutjnl-2012-304038","article-title":"Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol","volume":"62","author":"Reiberger","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.06.021_bib0114","first-page":"514","article-title":"Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients","volume":"88","author":"Salerno","year":"1993","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.06.021_bib0115","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/MD.0000000000000025","article-title":"Hepatic hydrothorax. Clinical features, management, and outcomes in 77 patients and review of the literature","volume":"93","author":"Badillo","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.dld.2021.06.021_bib0116","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.4254\/wjh.v9.i31.1197","article-title":"Hepatic hydrothorax: an update and review of the literature","volume":"9","author":"Garbuzenko","year":"2017","journal-title":"World J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0117","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jhep.2014.06.012","article-title":"CANONIC study investigators of the EASL-CLIF Consortium. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure","volume":"61","author":"Jalan","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0118","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jhep.2014.11.012","article-title":"The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure","volume":"62","author":"Jalan","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0119","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jhep.2010.11.008","article-title":"The MELD score in patients awaiting liver transplant: strengths and weaknesses","volume":"54","author":"Bernardi","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1211801","article-title":"Transfusion strategies for acute upper gastrointestinal bleeding","volume":"368","author":"Villanueva","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.06.021_bib0121","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0140-6736(95)92708-5","article-title":"Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients","volume":"346","author":"Levacher","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2021.06.021_bib0122","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0140-6736(97)05099-X","article-title":"Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial","volume":"350","author":"Avgerinos","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2021.06.021_bib0123","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1590-8658(01)80134-1","article-title":"Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study","volume":"33","author":"Borzio","year":"2001","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2021.06.021_bib0124","article-title":"Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding","volume":"9","author":"Chavez-Tapia","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.dld.2021.06.021_bib0125","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.dld.2013.07.015","article-title":"Management of infections in cirrhotic patients: report of a consensus conference","volume":"46","author":"Fagiuoli","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2021.06.021_bib0126","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/hep.20593","article-title":"Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial","volume":"41","author":"Shaheen","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0127","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1067\/mge.2003.46","article-title":"Endotracheal intubation for airway protection during endoscopy for severe upper GI hemorrhage","volume":"57","author":"Rudolph","year":"2003","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.dld.2021.06.021_bib0128","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.gie.2016.12.008","article-title":"Association of prophylactic endotracheal intubation in critically ill patients with upper GI bleeding and cardiopulmonary unplanned events","volume":"86","author":"Hayat","year":"2017","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.dld.2021.06.021_bib0129","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jhep.2012.07.038","article-title":"Delayed endoscopy increases re-bleeding and mortality in patients with hematemesis and active esophageal variceal bleeding: a cohort study","volume":"57","author":"Chen","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0130","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/S0618-8278(19)30028-3","article-title":"PS-022-Optimal timing of endoscopy is associated with lower 42-day mortality in variceal bleeding","volume":"70","author":"Laursen","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.dld.2021.06.021_bib0131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-119-1-199307010-00001","article-title":"Endoscopic ligation compared with sclerotherapy for the treatment of bleeding esophageal varices","volume":"119","author":"Laine","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dld.2021.06.021_bib0132","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.cgh.2015.07.012","article-title":"Varices and Variceal Hemorrhage in Cirrhosis: a New View of an Old Problem","volume":"13","author":"Garcia-Tsao","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0133","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/jgh.13303","article-title":"Early TIPS versus endoscopic therapy for secondary prophylaxis after management of acute esophageal variceal bleeding in cirrhotic patients: a meta-analysis of randomized controlled trials","volume":"31","author":"Halabi","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0134","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/hep.30182","article-title":"Preemptive-TIPS Improves Outcome in High-Risk Variceal Bleeding: an Observational Study","volume":"69","author":"Hern\u00e1ndez-Gea","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0135","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/gutjnl-2018-317057","article-title":"Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study","volume":"68","author":"Lv","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.06.021_bib0136","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jhep.2017.09.002","article-title":"Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results","volume":"68","author":"Thabut","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0137","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.20236","article-title":"Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis","volume":"39","author":"Avgerinos","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0138","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/liv.12452","article-title":"Drugs plus ligation to prevent rebleeding in cirrhosis: an updated systematic review","volume":"34","author":"Puente","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2021.06.021_bib0139","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1440-1746.2006.04169.x","article-title":"Factors predicting success of endoscopic variceal ligation for seconary prophylaxis of esophageal variceal bleeding","volume":"21","author":"Harewood","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0140","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1572-0241.2007.01191.x","article-title":"Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis","volume":"102","author":"Albillos","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.06.021_bib0141","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2016.11.001","article-title":"Beta adrenergic blockade and decompensated cirrhosis","volume":"66","author":"Reiberger","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0142","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/hep.29056","article-title":"A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis","volume":"65","author":"Villanueva","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0143","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1053\/j.gastro.2015.05.011","article-title":"Prevention of Rebleeding From Esophageal Varices in Patients with Cirrhosis Receiving Small-Diameter Stents Versus Hemodynamically Controlled Medical Therapy","volume":"149","author":"Sauerbruch","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0144","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/hep.1840160607","article-title":"Prevalence, classification and natural history of gastric varices: a long-term follow-upstudy in 568 portal hypertension patients","volume":"16","author":"Sarin","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0145","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1053\/j.tvir.2013.02.002","article-title":"Vascular anatomy and the morphologic and hemodynamic classifications of gastric varices and spontaneous portosystemic shunts relevant to the BRTO procedure","volume":"16","author":"Saad","year":"2013","journal-title":"Tech Vasc Interv Radiol"},{"key":"10.1016\/j.dld.2021.06.021_bib0146","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1440-1746.1996.tb00010.x","article-title":"Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration","volume":"11","author":"Kanagawa","year":"1996","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0147","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jhep.2010.09.031","article-title":"Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial","volume":"54","author":"Mishra","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0148","article-title":"Endoscopic injection of cyanoacrylate glue vs. other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension","volume":"5","author":"Rios","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.dld.2021.06.021_bib0149","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/gut.2009.192039","article-title":"Endoscopic cyanoacrylate injection vs. beta-blocker for secondary prophylaxis of gastric variceal bleed: a randomised controlled trial","volume":"59","author":"Mishra","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.06.021_bib0150","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1111\/j.1572-0241.2003.08769.x","article-title":"Cost-effectiveness of N-butyl-2-cyanoacrylate (histoacryl) glue injections vs. transjugular intrahepatic portosystemic shunt in the management of acute gastric variceal bleeding","volume":"98","author":"Mahadeva","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.06.021_bib0151","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1055\/s-2007-966591","article-title":"A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding","volume":"39","author":"Lo","year":"2007","journal-title":"Endoscopy"},{"key":"10.1016\/j.dld.2021.06.021_bib0152","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s10620-014-3485-8","article-title":"Balloon-Occluded Retrograde Transvenous Obliteration (BRTO) for Treatment of Gastric Varices: review and Meta-Analysis","volume":"60","author":"Park","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2021.06.021_bib0153","unstructured":"Runyon B.A. Management of adult patients with ascites due to cirrhosis: update 2012. www.aasld.org"},{"key":"10.1016\/j.dld.2021.06.021_bib0154","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/jhep.2003.50315","article-title":"The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club","volume":"38","author":"Moore","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0155","first-page":"164","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club","volume":"23","author":"Arroyo","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0156","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.dld.2018.11.117","article-title":"The clinical course of recurrent versus refractory ascites in outpatients with cirrhosis","volume":"51","author":"Tonon","year":"2019","journal-title":"Dig Liv Dis"},{"key":"10.1016\/j.dld.2021.06.021_bib0157","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/0016-5085(83)90198-1","article-title":"Randomized comparative study of efficacy of furosemide vs. spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system","volume":"84","author":"Perez-Ayuso","year":"1983","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0158","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-2007-1007295","article-title":"Hepatorenal disorders: role of the renin-angiotensin-aldosterone system","volume":"14","author":"Bernardi","year":"1994","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.dld.2021.06.021_bib0159","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000199198","article-title":"Importance of plasma aldosterone concentration on the natriuretic effect of spironolactone in patients with liver cirrhosis and ascites","volume":"31","author":"Bernardi","year":"1985","journal-title":"Digestion"},{"key":"10.1016\/j.dld.2021.06.021_bib0160","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2362.1990.tb01800.x","article-title":"Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance","volume":"20","author":"Angeli","year":"1990","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.dld.2021.06.021_bib0161","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/hep.1840140205","article-title":"A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients","volume":"14","author":"Gatta","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0162","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/0016-5085(83)90198-1","article-title":"Randomized comparative study of efficacy of furosemide vs. spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system","volume":"84","author":"Perez-Ayuso","year":"1983","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0163","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/gut.2008.176495","article-title":"Combined vs. sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial","volume":"59","author":"Angeli","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.06.021_bib0164","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-8278(03)00188-0","article-title":"Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety","volume":"39","author":"Santos","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0165","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1600-0676.1993.tb00624.x","article-title":"Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content","volume":"13","author":"Bernardi","year":"1993","journal-title":"Liver"},{"key":"10.1016\/j.dld.2021.06.021_bib0166","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1136\/gut.27.6.705","article-title":"Salt or no salt in the treatment of cirrhotic ascites: a randomised study","volume":"27","author":"Gauthier","year":"1986","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.06.021_bib0167","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/liv.12583","article-title":"Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life cross-sectional study","volume":"35","author":"Morando","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2021.06.021_bib0168","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/S0140-6736(18)30840-7","article-title":"Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial","volume":"391","author":"Caraceni","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2021.06.021_bib0169","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.13968","article-title":"Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites","volume":"39","author":"Di Pascoli","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2021.06.021_bib0170","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jhep.2018.08.006","article-title":"Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial","volume":"69","author":"Sol\u00e0","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0171","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jhep.2020.08.021","article-title":"ANSWER Study Investigators. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites","volume":"74","author":"Caraceni","year":"2021","journal-title":"J Hepatol."},{"key":"10.1016\/j.dld.2021.06.021_bib0172","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.gastro.2019.03.021","article-title":"Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis","volume":"157","author":"Fern\u00e1ndez","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0173","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0168-8278(96)80065-1","article-title":"Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists","volume":"25","author":"Lebrec","year":"1996","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0174","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1056\/NEJM200006083422303","article-title":"A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites","volume":"342","author":"Rossle","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.06.021_bib0175","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1053\/gast.2002.37073","article-title":"Transjugular intrahepatic portosystemic shunting vs. paracentesis plus albumin for refractory ascites in cirrhosis","volume":"123","author":"Gines","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0176","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1053\/gast.2003.50088","article-title":"The North American study for the treatment of refractory ascites","volume":"124","author":"Sanyal","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0177","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/hep.20364","article-title":"Randomized controlled study of TIPS vs. paracentesis plus albumin in cirrhosis with severe ascites","volume":"40","author":"Salerno","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0178","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00535-010-0282-9","article-title":"Transjugular intrahepatic portosystemic shunt vs. paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial","volume":"46","author":"Narahara","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.dld.2021.06.021_bib0179","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jhep.2005.06.005","article-title":"A metaanalysis of transjugular intrahepatic portosystemic shunt vs. paracentesis for refractory ascites","volume":"43","author":"Albillos","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0180","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1053\/j.gastro.2005.07.031","article-title":"Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis","volume":"129","author":"D'Amico","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0181","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1478-3231.2005.01095.x","article-title":"Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis","volume":"25","author":"Deltenre","year":"2005","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2021.06.021_bib0182","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004889.pub2","article-title":"TIPS vs. paracentesis for cirrhotic patients with refractory ascites","author":"Saab","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.dld.2021.06.021_bib0183","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1053\/j.gastro.2007.06.020","article-title":"Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data","volume":"133","author":"Salerno","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0184","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.3748\/wjg.v20.i10.2704","article-title":"TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis","volume":"20","author":"Bai","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2021.06.021_bib0185","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/MCG.0b013e3182a115e9","article-title":"Prophylactic use of transjugular intrahepatic portosystemic shunt aids in the treatment of refractory ascites: metaregression and trial sequential meta-analysis","volume":"48","author":"Chen","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.dld.2021.06.021_bib0186","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1053\/j.gastro.2003.11.016","article-title":"Improved clinical outcome using polytetrafluoroethylene- coated stents for TIPS: results of a randomized study","volume":"126","author":"Bureau","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0187","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/j.gastro.2016.09.016","article-title":"Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites","volume":"152","author":"Bureau","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0188","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.cgh.2018.03.027","article-title":"Cost Effectiveness of Early Insertion of Transjugular Intrahepatic Portosystemic Shunts for Recurrent Ascites","volume":"16","author":"Shen","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0189","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jhep.2017.05.006","article-title":"Eight millimeter covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding","volume":"67","author":"Wang","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0190","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.cgh.2018.01.029","article-title":"Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis","volume":"16","author":"Schepis","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0191","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00270-018-2040-y","article-title":"Transjugular Intrahepatic Portosystemic Shunt Using the New Gore Viatorr Controlled Expansion Endoprosthesis: prospective, Single-Center, Preliminary Experience","volume":"42","author":"Miraglia","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.dld.2021.06.021_bib0192","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.dld.2016.10.011","article-title":"AISF TIPS Special Conference. Consensus conference on TIPS management: techniques, indications, contraindications","volume":"49","author":"Fagiuoli","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2021.06.021_bib0193","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/liv.13615","article-title":"ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis","volume":"38","author":"Bucsics","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2021.06.021_bib0194","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jhep.2012.12.020","article-title":"Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study","volume":"58","author":"Bellot","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0195","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jhep.2017.06.010","article-title":"Alfapump system vs. large volume paracentesis for refractory ascites: a multicenter randomized controlled study","volume":"67","author":"Bureau","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0196","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s11136-018-1813-8","article-title":"Patients with refractory ascites treated with Alfapump\u00ae system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study","volume":"27","author":"Stepanova","year":"2018","journal-title":"Qual Life Res"},{"key":"10.1016\/j.dld.2021.06.021_bib0197","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/lt.24763","article-title":"Effects of alfapump\u2122 system on kidney and circulatory function in patients with cirrhosis and refractory ascites","volume":"23","author":"Sol\u00e0","year":"2017","journal-title":"Liver Transpl"},{"key":"10.1016\/j.dld.2021.06.021_bib0198","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/apt.14331","article-title":"Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis","volume":"46","author":"Stirnimann","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.06.021_bib0199","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jhep.2009.11.025","article-title":"The evaluation of renal function and disease in patients with cirrhosis","volume":"52","author":"Francoz","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0200","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1111\/liv.12852","article-title":"New ICA criteria for the diagnosis of acute kidney injury in cirrhotic patients: can we use an imputed value of serum creatinine?","volume":"35","author":"Rosi","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2021.06.021_bib0201","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2018.12.030","article-title":"Estimation of renal function in patients with liver cirrhosis: impact of muscle mass and sex","volume":"70","author":"Yoo","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0202","first-page":"1","article-title":"Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and management of Chronic Kidney Disease","volume":"3","year":"2013","journal-title":"Kidney Int. (suppl.)"},{"key":"10.1016\/j.dld.2021.06.021_bib0203","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dld.2021.06.021_bib0204","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jhep.2014.12.029","article-title":"Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites","volume":"62","author":"Angeli","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0205","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/hep.29303","article-title":"Significance of oliguria in critically ill patients with chronic liver disease","volume":"66","author":"Amathieu","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0206","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/jhep.2003.50084","article-title":"Acute renal failure in patients with cirrhosis: perspectives in the age of MELD","volume":"37","author":"Moreau","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0207","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jhep.2012.03.015","article-title":"Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis","volume":"57","author":"Fagundes","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0208","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/hep.26980","article-title":"Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury","volume":"60","author":"Belcher","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0209","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.cgh.2016.11.035","article-title":"Urine Interleukin 18 and Lipocalin 2 Are Biomarkers of Acute Tubular Necrosis in Patients With Cirrhosis: a Systematic Review and Meta-analysis","volume":"15","author":"Puthumana","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0210","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/hep.30592","article-title":"Neuthrophil Gelatinase-Associatted Lipocalin for assessment of acute kidneu injury in cirrhosis: a prospective studies. urine NGAL. Relevance for the differential diagnosis and clinical outcomes","volume":"70","author":"Huelin","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0211","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/gast.2002.32364","article-title":"Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study","volume":"122","author":"Moreau","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0212","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/jhep.2002.35819","article-title":"Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study","volume":"36","author":"Ortega","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0213","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized prospective double blind, placebo controlled study of terlipressin for type 1 hepatorenal syndrome","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0214","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study","volume":"134","author":"Martin-Llahi","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0215","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"REVERSE Study Investigators Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1","volume":"150","author":"Boyer","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0216","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jhep.2013.12.032","article-title":"Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis","volume":"60","author":"Rodriguez","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0217","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial","volume":"62","author":"Cavallin","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0218","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/hep.28396","article-title":"Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study","volume":"63","author":"Cavallin","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0219","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005162.pub3","article-title":"Terlipressin for hepatorenal syndrome","author":"Gluud","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.dld.2021.06.021_bib0220","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S2468-1253(16)30157-1","article-title":"Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis","volume":"2","author":"Facciorusso","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0221","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","article-title":"Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study","volume":"47","author":"Alessandria","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0222","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/jhep.2002.34343","article-title":"Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study","volume":"36","author":"Duvoux","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0223","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jhep.2012.01.012","article-title":"Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study","volume":"56","author":"Singh","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0224","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","article-title":"An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response","volume":"103","author":"Sharma","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.06.021_bib0225","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/hep.30208","article-title":"Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure","volume":"71","author":"Arora","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0226","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s10620-006-9312-0","article-title":"Octreotide\/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome","volume":"52","author":"Esrailian","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2021.06.021_bib0227","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1523-1755.2005.00408.x","article-title":"Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy","volume":"68","author":"Wong","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.dld.2021.06.021_bib0228","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/08860229509026250","article-title":"Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis","volume":"17","author":"Keller","year":"1995","journal-title":"Ren Fail"},{"key":"10.1016\/j.dld.2021.06.021_bib0229","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s11255-013-0527-7","article-title":"Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients","volume":"46","author":"Sourianarayanane","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.dld.2021.06.021_bib0230","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/liv.13389","article-title":"Renal replacement therapy in critically ill liver cirrhotic patients-outcome and clinical implications","volume":"37","author":"Staufer","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2021.06.021_bib0231","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jhep.2018.04.025","article-title":"The intensive care unit course and outcome in acute-on-chronic liver failure are comparable to other populations","volume":"69","author":"Meersseman","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0232","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jamcollsurg.2007.04.006","article-title":"Early renal replacement therapy in patients with postoperative acute liver failure associated with acute renal failure: effect on postoperative outcomes","volume":"205","author":"Wu","year":"2007","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.dld.2021.06.021_bib0233","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1603017","article-title":"Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit","volume":"375","author":"Gaudry","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.06.021_bib0234","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1001\/jama.2016.5828","article-title":"Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: the ELAIN Randomized Clinical Trial","volume":"315","author":"Zarbock","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2021.06.021_bib0235","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jhep.2012.06.024","article-title":"Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice","volume":"57","author":"Angeli","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0236","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1111\/ajt.13408","article-title":"A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: toward a \"Blended Principle Model\"","volume":"15","author":"Cillo","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.dld.2021.06.021_bib0237","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/lt.22395","article-title":"Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1","volume":"17","author":"Boyer","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.dld.2021.06.021_bib0238","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00007890-199502150-00010","article-title":"Impact of pretransplant renal function on survival after liver transplantation","volume":"59","author":"Gonwa","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2021.06.021_bib0239","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2003.09.019","article-title":"Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study","volume":"40","author":"Restuccia","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0240","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/lt.24210","article-title":"Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: effects on kidney function and transplantation outcomes","volume":"21","author":"Rodriguez","year":"2015","journal-title":"Liver Transpl"},{"key":"10.1016\/j.dld.2021.06.021_bib0241","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/ajt.13631","article-title":"Simultaneous Liver-Kidney Allocation Policy: a Proposal to Optimize Appropriate Utilization of Scarce Resources","volume":"16","author":"Formica","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.dld.2021.06.021_bib0242","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/j.jhep.2014.11.045","article-title":"Acute-on-chronic liver failure: a new syndrome that will re-classify cirrhosis","volume":"62","author":"Arroyo","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0243","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.dld.2021.06.021_bib0244","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1136\/gutjnl-2017-314240","article-title":"Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis","volume":"67","author":"Fern\u00e1ndez","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.06.021_bib0245","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2018.10.027","article-title":"Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe","volume":"70","author":"Fern\u00e1ndez","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0246","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1053\/j.gastro.2018.12.005","article-title":"Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide","volume":"156","author":"Piano","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0247","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/hep.27849","article-title":"Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis","volume":"62","author":"Gustot","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0248","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1053\/j.gastro.2018.12.007","article-title":"Factors Associated with Survival of Patients With Severe Acute-On-Chronic Liver Failure Before and After Liver Transplantation","volume":"156","author":"Sundaram","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0249","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/hep.30624","article-title":"Patients With Acute on Chronic Liver Failure Grade 3 Have Greater 14-Day Waitlist Mortality Than Status-1a Patients","volume":"70","author":"Sundaram","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0250","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jhep.2018.12.008","article-title":"Acute-on-chronic liver failure in patients with alcohol-related liver disease","volume":"70","author":"Gustot","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0251","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1053\/j.gastro.2011.11.027","article-title":"Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure","volume":"142","author":"Garg","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0252","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.3748\/wjg.v19.i7.1104","article-title":"Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure","volume":"19","author":"Duan","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2021.06.021_bib0253","doi-asserted-by":"crossref","first-page":"725","DOI":"10.5966\/sctm.2012-0034","article-title":"Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients","volume":"1","author":"Shi","year":"2012","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.dld.2021.06.021_bib0254","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1086\/514940","article-title":"Spontaneous Bacterial Peritonitis","volume":"27","author":"Such","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2021.06.021_bib0255","doi-asserted-by":"crossref","first-page":"568","DOI":"10.7326\/0003-4819-60-4-568","article-title":"Spontaneous peritonitis and bacteremia in Laennec's Cirrhosis Caused by Enteric Organisms. A Relatively Common but Rarely Recognized Syndrome","volume":"60","author":"Conn","year":"1964","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dld.2021.06.021_bib0256","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cgh.2011.02.031","article-title":"Immune Dysfunction and Infections in Patients With Cirrhosis","volume":"9","author":"Bonnel","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0257","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/S0168-8278(97)80474-6","article-title":"Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites","volume":"26","author":"Guarner","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0258","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jhep.2013.07.044","article-title":"Pathological bacterial translocation in liver cirrhosis","volume":"60","author":"Wiest","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0259","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.3748\/wjg.15.3845","article-title":"Ascitic fluid analysis for diagnosis and monitoring of spontaneous bacterial peritonitis","volume":"15","author":"Riggio","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2021.06.021_bib0260","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0016-5085(90)91300-U","article-title":"Utility of an algorithm in differentiating spontaneous from secondary bacterial peritonitis","volume":"98","author":"Akriviadis","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0261","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/0016-5085(88)90372-1","article-title":"Optimization of ascitic fluid culture technique","volume":"95","author":"Runyon","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0262","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jhep.2014.01.024","article-title":"Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013","volume":"60","author":"Jalan","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0263","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/hep.27941","article-title":"The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: results of a randomized, controlled clinical trial","volume":"63","author":"Piano","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.021_bib0264","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.dld.2017.01.157","article-title":"Antibiotic stewardship and empirical antibiotic treatment: how can they get along?","volume":"49","author":"Zuccaro","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2021.06.021_bib0265","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/liv.14109","article-title":"Comparative efficacy of long-term antibiotic treatments in the primary prophylaxis of spontaneous bacterial peritonitis","volume":"39","author":"Facciorusso","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2021.06.021_bib0266","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/1751-2980.12132","article-title":"A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients","volume":"15","author":"Lontos","year":"2014","journal-title":"J Dig Dis"},{"key":"10.1016\/j.dld.2021.06.021_bib0267","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.06.021_bib0268","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/MEG.0000000000000724","article-title":"Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis","volume":"28","author":"Elfert","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0269","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.dld.2016.12.019","article-title":"Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma","volume":"49","author":"Zanetto","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2021.06.021_bib0270","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jhep.2009.03.013","article-title":"Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development","volume":"51","author":"Zocco","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0271","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1097\/TP.0b013e31826e8e53","article-title":"Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review","volume":"94","author":"Rodriguez-Castro","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2021.06.021_bib0272","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1478-3231.2012.02785.x","article-title":"Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis","volume":"32","author":"Senzolo","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2021.06.021_bib0273","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1148\/radiol.12112236","article-title":"Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis","volume":"265","author":"Luca","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.dld.2021.06.021_bib0274","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/ajg.2012.313","article-title":"The effectiveness of current acute variceal bleed treatments in unselected cirrhotic patients: refining short-term prognosis and risk factors","volume":"107","author":"Amitrano","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.06.021_bib0275","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2014.218","article-title":"Liver: PVT in cirrhosis, not always an innocent bystander","volume":"12","author":"Senzolo","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0276","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41424-018-0043-2","article-title":"IRSVT study investigators. Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis","volume":"9","author":"Senzolo","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.dld.2021.06.021_bib0277","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41395-018-0421-0","article-title":"BO-LIVES (BOlogna LIVEr vascular Studies). Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis","volume":"114","author":"Pettinari","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.06.021_bib0278","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/j.gastro.2017.04.042","article-title":"Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: a Systematic Reviewand Meta-analysis","volume":"153","author":"Loffredo","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.06.021_bib0279","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MEG.0000000000001237","article-title":"A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis","volume":"31","author":"Rodriguez-Castro","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0280","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.cgh.2012.01.012","article-title":"Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis","volume":"10","author":"Delgado","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0281","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jhep.2015.07.040","article-title":"Vascular diseases of the liver","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0282","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/MEG.0000000000001219","article-title":"The role of transjugular intrahepatic portosystemic shunt in the management of portal vein thrombosis: a systematic review and meta-analysis","volume":"30","author":"Valentin","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0283","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1136\/gut.2010.228023","article-title":"Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis","volume":"60","author":"Luca","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.06.021_bib0284","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jvir.2010.07.028","article-title":"Endovascular treatment for nonacute symptomatic portal venous thrombosis through intrahepatic portosystemic shunt approach","volume":"22","author":"Luo","year":"2011","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.dld.2021.06.021_bib0285","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/apt.15044","article-title":"Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis","volume":"49","author":"Rodrigues","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.06.021_bib0286","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1365-2036.2006.02820.x","article-title":"Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation","volume":"23","author":"Senzolo","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.06.021_bib0287","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1007\/s00330-015-3777-1","article-title":"Percutaneous transhepatic balloon-assisted transjugular intrahepatic portosystemic shunt for chronic, totally occluded, portal vein thrombosis with symptomatic portal hypertension: procedure technique, safety, and clinical applications","volume":"25","author":"Chen","year":"2015","journal-title":"Eur Radiol"},{"key":"10.1016\/j.dld.2021.06.021_bib0288","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jvir.2017.08.005","article-title":"Pretransplantation Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt Creation for Chronic Portal Vein Thrombosis: final Analysis of a 61-Patient Cohort","volume":"28","author":"Thornburg","year":"2017","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.dld.2021.06.021_bib0289","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jhep.2013.03.010","article-title":"How to improve care in outpatients with cirrhosis and ascites: a new model of care coordination by consultant hepatologists","volume":"59","author":"Morando","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.06.021_bib0290","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/liv.13620","article-title":"Palliative care in decompensated cirrhosis: a review","volume":"38","author":"Langberg","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2021.06.021_bib0291","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.3748\/wjg.v17.i18.2273","article-title":"Management of liver cirrhosis between primary care and specialists","volume":"17","author":"Grattagliano","year":"2011","journal-title":"World J Gastroenterol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821003352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821003352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:17:06Z","timestamp":1761625026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865821003352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":291,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1590865821003352"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2021.06.021","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF)","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2021.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}